Comparative analysis of the efficacy and safety of Lynparza and Pamiparib

Olaparib (Olaparib) and Pamiparib (Pamiparib) are oral PARP inhibitors, mainly used to treat ovarian cancer, breast cancer and some solid tumors that are positive for BRCA gene mutations. Both inhibit the activity of PARP enzyme and prevent the repair of DNA single-strand breaks, leading to the accumulation of DNA damage in tumor cells and inducing the apoptosis of cancer cells. Olaparib is the first approved PARP inhibitor with abundant clinical data; Pamiparib is a new PARP inhibitor subsequently developed, and some clinical studies have shown that it has potential advantages in efficacy and tolerability.

Multiple clinical trials have shown that olaparib can achieve a median progression-free survival (PFS) of 19 to BRCA mutation-positive ovarian cancer patients with recurrent or maintenance treatment. 21 months, while Pamiparib’s PFS in a similar patient group is about 17 to 20 months, and the efficacy is roughly the same. Some studies have shown that pamiparib shows higher blood concentrations and better anti-tumor activity in Chinese patients, suggesting that it may have certain advantages in specific groups of people. But in general, the efficacy of the two in main indications is similar, and the appropriate drug needs to be selected based on the patient's specific conditions.

Common adverse reactions of olaparib include anemia, thrombocytopenia, nausea, fatigue and mild gastrointestinal symptoms, and most of them are manageable. The spectrum of adverse reactions of pamiparib is similar, but clinical data show that its hematological toxicity is slightly lower, the incidence of gastrointestinal reactions is slightly lower than that of olaparib, and some patients are more likely to tolerate long-term treatment. However, rare serious adverse events such as bone marrow suppression or abnormal liver function still require close monitoring, and both require regular review of blood routine and liver and kidney function to ensure safety.

In clinical practice, the choice of olaparib or pamiparib should be based on the patient's previous treatment history, gene mutation status, drug availability, and economic factors. Olaparib is suitable for patients who require extensive clinical experience and long-term follow-up data, while pamiparib is well tolerated and has controllable blood concentration in some Asian patients, and can be used as an alternative. Overall, both are important targeted therapeutic drugs for BRCA mutation-related tumors, and their rational use can effectively prolong patients’ progression-free survival and maintain their quality of life.

Reference materials:https://www.drugs.com/